NEW
YORK, Dec. 26, 2024 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders of Kyverna
Therapeutics, Inc. (NASDAQ: KYTX).
Shareholders who purchased shares of KYTX during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=118168&from=4
CLASS PERIOD: This lawsuit is on behalf of all those who
purchased or otherwise acquired Kyverna common stock pursuant
and/or traceable to the Company's offering documents issued in
connection with its February 2024
initial public offering.
ALLEGATIONS: The complaint alleges that during the
class period, Defendants issued materially false and/or misleading
statements and/or failed to disclose that: (i) the strategy to best
accomplish the IPO; (ii) the terms of the IPO, including the price
at which Kyverna's common stock would be sold; (iii) the language
to be used in the Offering Documents; (iv) what disclosures about
Kyverna would be made in the Offering Documents; and (v) what
responses would be made to the SEC in connection with its review of
the Offering Documents. As a result of those constant contacts and
communications between the underwriter defendants' representatives
and Kyverna's management, directors, and lawyers, at a minimum, the
underwriterd defendants should have known of Kyverna's undisclosed
then-existing problems and plans, and the Offering Document's
materially inaccurate, misleading, and incomplete statements and
omissions, as detailed herein.
DEADLINE: February 7, 2025
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=118168&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of KYTX during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is February 7, 2025. There is no cost
or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross
Law Firm is committed to ensuring that companies adhere to
responsible business practices and engage in good corporate
citizenship. The firm seeks recovery on behalf of investors who
incurred losses when false and/or misleading statements or the
omission of material information by a company lead to artificial
inflation of the company's stock. Attorney advertising. Prior
results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/contact-the-gross-law-firm-by-february-7-2025-deadline-to-join-class-action-against-kyverna-therapeutics-inckytx-302338667.html
SOURCE The Gross Law Firm